Interference of bone marrow CD56(+) mesenchymal stromal cells in minimal residual disease investigation of neuroblastoma and other CD45(-)/CD56(+) pediatric malignancies using flow cytometry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F19%3A10395191" target="_blank" >RIV/00064203:_____/19:10395191 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/19:10395191

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=F77S0Rn1y9" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=F77S0Rn1y9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/pbc.27799" target="_blank" >10.1002/pbc.27799</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Interference of bone marrow CD56(+) mesenchymal stromal cells in minimal residual disease investigation of neuroblastoma and other CD45(-)/CD56(+) pediatric malignancies using flow cytometry

Popis výsledku v původním jazyce

Background Bone marrow (BM) samples obtained from minimal residual disease (MRD)-negative children with B-cell acute lymphoblastic leukemia (B-ALL) were used in our laboratory as negative biological controls for the development of a neuroblastoma (NBL) flow-cytometric (FC) protocol. The accidental, but systematic, identification of rare cell populations (RCP) mimicking NBL cells (CD45(-)/CD56(+)) in these samples indicated the need for their thorough immunophenotypic identification, in order to elucidate their possible interference in NBL-MRD assessment. Procedure RCP observed in BM samples from 14 children recovering from BM aplasia due to intensive chemotherapy for B-ALL were investigated with the following markers: CD81, CD200, CD24, GD2, CD73, CD13, CD90, CD146, CD9, CD117, CD10, CD99, and NG2. BM samples from six newly diagnosed patients with NBL and an NBL cell line were simultaneously investigated as positive controls. Results The frequency of RCP in B-ALL BM samples was &lt; 1/1 x 10(4) cells (bulky lysis), and their immunophenotypic profile was indicative of CD56(+) mesenchymal stromal cells (MSCs) (CD45(-), CD90(+), CD146(+), CD73(+)). Also, RCP expressed CD81 and CD200, simulating NBL cells. The most useful discriminative markers for CD56(+) MSCs were CD13 and CD73. An appropriate protocol consisting of two tubes with seven color combinations was further proposed: SYTO-16, GD2 (first tube) or CD73 (second tube)-PE, CD24-ECD, CD13-PC5.5, CD45-PC7, CD81-APC, and CD56-APC700. Conclusions RCP that were immunophenotypically similar to NBL were identified as CD56(+) MSCs. As these cells might pose an obstacle to accurate NBL disease assessment by FC, especially MRD, an enhanced NBL-FC protocol is proposed for prospective evaluation.

Název v anglickém jazyce

Interference of bone marrow CD56(+) mesenchymal stromal cells in minimal residual disease investigation of neuroblastoma and other CD45(-)/CD56(+) pediatric malignancies using flow cytometry

Popis výsledku anglicky

Background Bone marrow (BM) samples obtained from minimal residual disease (MRD)-negative children with B-cell acute lymphoblastic leukemia (B-ALL) were used in our laboratory as negative biological controls for the development of a neuroblastoma (NBL) flow-cytometric (FC) protocol. The accidental, but systematic, identification of rare cell populations (RCP) mimicking NBL cells (CD45(-)/CD56(+)) in these samples indicated the need for their thorough immunophenotypic identification, in order to elucidate their possible interference in NBL-MRD assessment. Procedure RCP observed in BM samples from 14 children recovering from BM aplasia due to intensive chemotherapy for B-ALL were investigated with the following markers: CD81, CD200, CD24, GD2, CD73, CD13, CD90, CD146, CD9, CD117, CD10, CD99, and NG2. BM samples from six newly diagnosed patients with NBL and an NBL cell line were simultaneously investigated as positive controls. Results The frequency of RCP in B-ALL BM samples was &lt; 1/1 x 10(4) cells (bulky lysis), and their immunophenotypic profile was indicative of CD56(+) mesenchymal stromal cells (MSCs) (CD45(-), CD90(+), CD146(+), CD73(+)). Also, RCP expressed CD81 and CD200, simulating NBL cells. The most useful discriminative markers for CD56(+) MSCs were CD13 and CD73. An appropriate protocol consisting of two tubes with seven color combinations was further proposed: SYTO-16, GD2 (first tube) or CD73 (second tube)-PE, CD24-ECD, CD13-PC5.5, CD45-PC7, CD81-APC, and CD56-APC700. Conclusions RCP that were immunophenotypically similar to NBL were identified as CD56(+) MSCs. As these cells might pose an obstacle to accurate NBL disease assessment by FC, especially MRD, an enhanced NBL-FC protocol is proposed for prospective evaluation.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pediatric Blood and Cancer

ISSN

1545-5009

e-ISSN

—

Svazek periodika

66

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

e27799

Kód UT WoS článku

000472549200002

EID výsledku v databázi Scopus

2-s2.0-85065499634